Controlled activation of complement components for use as endogenous adjuvant

A pharmaceutical composition comprising a therapeutically effective dose of at least one recombinant human C3-derivative having the SEQ ID Nos:

• 1-3 and at least one antigen for vaccination, and wherein the recombinant human C3-derivative is coated or absorbed on or embedded in a first matrix, wherein the first matrix is selected as to enable sustained release of the recombinant human C3-derivative, and wherein, optionally, the antigen is coated or absorbed on or embedded in a second matrix different from the first matrix, wherein the second matrix is an adjuvant providing a depot effect for antigen presentation, and wherein the first and/or the second matrix is a thermogelling hydrogel having a gelling temperature between 20° C. and 40° C.;
• wherein the thermogelling hydrogel is a thermogelling PLGA-PEG-PLGA hydrogel wherein the gelling temperature is between 20° C. and 40° C.